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Abstract: A simple colorimetric probe for the selective and sensitive detection of neurotransmitter 
norepinephrine (NE), an important biomarker in the detection of tumors such as 
pheochromocytoma and paraganglioma, is described. The sensing strategy is based on the use 
of spherical gold nanoparticles functionalized with benzaldehyde and boronic acid-terminated 
moieties. A double molecular recognition involving on the one hand the aromatic aldehyde and 
the aminoalcohol group of NE, and on the other hand the boronic acid and the catechol moiety of 
the neurotransmitter, results in analyte triggered aggregation of the gold nanoparticles, leading to 
a bathochromic shift of the SPR band in the UV-vis spectrum of the probe and a clear change in 
the color of the solution from red to blue. Probe P1 shows a remarkable selectivity towards NE 
versus other catecholamine neurotransmitters (dopamine and epinephrine) and selected 
biomolecules (5-HIAA, L-Tyr, glucose, uric acid, Lys and glutamic acid). Moreover, a linear 
response to NE in the 0-1 M concentration range was observed and limit of detection of 0.07 µM 
in aqueous media was determined by UV-vis spectroscopy. The sensitivity of the probe towards 
NE in synthetic urine was also evaluated. In this medium, a limit of detection of 0.09 µM was 
obtained which falls within the range of clinical interest. 
 






Norepinephrine (NE) or noradrenaline, also known as the “hormone of the stress” is a 
hormone and a neurotransmitter secreted by noradrenergic neurons in the sympathetic and 
central nervous system. NE plays important roles in physiological processes such as stress, [1-
2] anxiety, [3-4] sleep, [5] and memory. Additionally, NE is involved in the fight-or-flight response, 
triggering the release of glucose and increasing heart rate and blood flow to skeletal muscle. [7] 
Furthermore, it also regulates the function of certain types of immune cells (e.g., T and NK 
cells).[8] Pathologies such as depression,[9-10] Alzheimer’s disease,[11] and Parkinson's 
disease are associated with low levels of NE.[12] Conversely, high NE levels are indicative of 
pheochromocytoma and paraganglioma, two neuroendocrine tumors, which start in the adrenal 
medulla and extra-adrenal paraganglia respectively and secrete large amounts of NE.[13-14] This 
increases NE levels in patients’ urine and causes hypertension, fast heart rate, headache, 
sweating and chest or abdominal pain.[15] In addition, human immunodeficiency virus-1 (HIV-1) 
replication is accelerated by NE via protein kinase A-dependent effects on cytokine 
production.[16]  
Given the importance of NE as biomarker for the early diagnosis of the previously 
commented pathologies, the development of effective and simple methods for the detection and 
quantitative determination of NE is highly desirable. 
In recent years, some analytical methods have been developed for the determination of 
NE, such as high performance liquid chromatography (HPLC), [17-18] fluorometric [19-20] and 
electrochemical techniques [21-23]. Although these reported methods are able to determine 
correctly the presence of NE, in general expensive equipment and complicated sample pre-
treatment is needed. Hence, the development of fast, low cost, sensitive and selective techniques 
for the specific and simple detection of NE in biological fluids is of great importance. 
The use of chromogenic sensors and probes is an appealing alternative to overcome 
some limitations of traditional instrumental methods, because their low cost and operational 
simplicity, allow on-site detection, and require simple equipment or no instrumentation at all [24]. 
Remarkably in spite of them being of much interest, very few colorimetric methods have been 
developed to detect NE [25-30]. Moreover, most of these methods are based on the use of 
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catecholamines as reducing agents, which lead to reduced selectivity to NE in the presence of 
other catecholamines, such as dopamine or epinephrine (see Table S3 Supporting Information).  
Gold nanoparticles (AuNPs) are excellent materials, which have been successfully 
applied for the design of colorimetric probes. [31-33] In general, the detection strategy relies on 
the observed color changes that arise upon analyte-triggered aggregation or the redispersion of 
nanoparticles. Colloidal solutions of dispersed AuNPs, a with particle size between 5-30 nm, 
exhibit a deep red color and a high molar extinction coefficient due to a surface plasmon 
resonance (SPR) band. Moreover, AuNPs can be easily functionalized on their surface with a 
broad range of organic molecules or biological macromolecules, which selectively interact with 
the target analyte. This interaction triggers the aggregation of AuNPs, resulting in interparticle 
surface plasmon coupling. This results in an important bathochromic shift of the SPR band and a 
change in the color of the solution from red to blue, which can be seen with the naked eye at very 
low analyte concentrations. [34-37] For instance, the implementation of double-functionalized 
AuNPs as probes for the selective colorimetric detection of neurotransmitters such as dopamine 
[38] or serotonin [39] has been previously reported. 
Based on the aforementioned facts, and following our interest in developing colorimetric 
methods for the fast, simple and selective detection of biomarkers, we report herein the use of 
bifunctionalized AuNPs as probes for the colorimetric detection of NE, through the double 
molecular recognition of the catechol and aminoalcohol moieties. 
The sensing strategy is sketched in Scheme 1. Probe P1 consists of AuNPs (ca. 14 nm), 
functionalized on their surface with two different ligands, 4-(liponyloxy)benzaldehyde (L1) and 4-
mercatophenylboronic acid (L2). The terminal aldehyde of L1 was chosen to react with the 
aminoalcohol group of NE to form an oxazolidine,[40,41] whereas L2 plays a double role: (i) the 
boronic acid group is able to react with the catechol moiety in NE to form stable boronate groups 
[42-43]; (ii) the ligand also acts as a stabilizer for AuNPs. A double interaction between NE and 
the dispersed gold nanoparticles was expected to trigger their aggregation leading to a shift of 
the AuNPs SPR band, with the resulting change in the color of the solution (from red to blue). 
 
Scheme 1. Sensing strategy for the colorimetric detection of norepinephrine (NE) using gold nanoparticles functionalized 






2.1 Synthesis of probe P1 
Probe P1 was synthesized from freshly prepared citrate-stabilized gold nanoparticles of ca. 14 
nm diameter (see Supp Info) by a ligand-exchange reaction with L1 and L2, which was performed 
as follows: First L2 (20 µl, 0.5 mM in DMF) was added to an aqueous dispersion of the as-
prepared citrate-coated AuNPs (10 mL) and the mixture stirred for 1 min at room temperature. 
Then L1 (20 µl, 0.5 mM in DMF) was added to the solution and the mixture was stirred at room 
temperature for 1 h. The resulting suspension of nanoparticles was centrifuged (10 min, 11000 
rpm), the supernatant was decanted and the nanoparticles redispersed again in Mili-Q water (18.2 
MΩ cm-1). This procedure was repeated twice to yield probe P1. 
2.2 Sensing studies 
NE solutions of different concentrations were freshly prepared at pH 6.5 in 10 mM phosphate 
buffer at room temperature. Then 200 μL of the NE solution at the corresponding concentration 
was added to 200 μL of the solution of P1 (8.1 X 10-10 M). The resulting mixture of NE and probe 
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P1 (400 μL) was incubated for 5 min and then the corresponding UV-vis spectra was recorded at 
room temperature. The same protocol was followed in the study of interferences.  
The assays run with the optimized probe (OP1) were performed by adding 20 μL of NE (500 μM, 
final concentration) to 200 μL of P1 and incubating for 1 minute. Next 180 μL of the NE problem 
solution at different concentrations were added resulting in a final volume of 400 μL. UV-vis 
measurements were performed after an incubation time of 5 min. In order to ensure that the 
priming of the probe does not bias the results, 220 μL of the mother solution of OP1 plus 180 μL 
of phosphate buffer is used as blank (0 added NE) and compared with the signal of the optimized 
probe upon addition of external NE. This procedure of priming gold nanoparticles-based probes 
has been carried out based on previously reported studies. [38] 
SurineTM (synthetic urine negative control) was used for the measurements of NE in urine. To 
take these measurements, OP1 (200 μL) and 200 μL of the NE solutions in 10% of the synthetic 
urine were mixed, incubated for 5 min, and their UV-vis spectra were recorded. 
 
3. Results and Discussion 
Probe P1, which is depicted in Scheme 1, consists of spherical gold nanoparticles 
functionalized with 4-(liponyloxy)benzaldehyde (L1) and 4-mercaptophenyl boronic acid (L2), 
which are attached to the AuNPs' surface through the formation of stable Au-S bonds. 
L1 was prepared from lipoic acid and p-hydroxybenzaldehyde in the presence of DCC and 
DMAP with an overall 86 % yield (Scheme S1). 
The bifunctionalized AuNPs were prepared as follows: First citrate-capped AuNPs were 
synthesized by reduction of chloroauric acid with sodium citrate in boiling water, following the 
Turkevich-Frens method. [44-46] Then, citrate was displaced from the surface of the 
nanoparticles, in a ligand exchange reaction, by the addition of L1 and L2 (1:1 molar ratio). A 
repeated process of centrifugation, elimination of the supernatants and redispersion in water 
yielded probe P1. 
In order to characterize P1, transmission electron microscopy (TEM), dynamic light 
scattering (DLS), Fourier-transform infrared spectroscopy (FTIR), inductively coupled plasma 
mass spectrometry (ICP-MS) and UV-Vis spectroscopy measurements were performed. 
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Monodisperse AuNPs with an average size of 14 ± 2 nm were observed by TEM (Figure S2). The 
hydrodynamic diameter of nanoparticles, determined by DLS, increased from 16.7 nm for the 
citrate-stabilized AuNPs to 20.5 nm for the bifunctionalized AuNPs P1 (Figure S3 A). The double 
molecular functionalization was confirmed by FTIR spectra, which showed the presence of 
absorption bands corresponding to L1 and L2 (see Figure S5). Finally, the amount of ligands L1 
and L2 per gold nanoparticle was calculated from ICP-MS studies (B and S) resulting in ca. 1400 
and 930 molecules respectively, corresponding to a L1/L2 molar ratio of 1.5:1 (Table S1). 
The aqueous suspensions of P1 presented the characteristic red wine color and their UV-
vis spectrum showed the presence of an intense SPR peak at 523 nm in the, typical of AuNPs 
with an average size smaller than 30 nm [47-48]. A final concentration of the P1 nanoparticles of 
ca. 8.12 X 10-10 M was calculated from their UV-vis spectra, considering a molar extinction 
coefficient ε = 3.15x108 M-1 cm-1 [49].  
The suspensions of P1 were stored in the refrigerator until their use. No changes in the 
characteristic SPR absorption band or in the color of the solutions were observed after more than 
3 weeks, which evidences the good stability of P1. 
Before starting the sensing studies with P1, a preliminary 1HNMR study of a mixture of 
NE and 4-methoxybenzaldehyde in MeOH/H2O at room temperature confirmed the reaction of 
the aromatic aldehyde with the aminoalcohol group of NE (see Fig S17 in SuppInfo). 
The sensing capability of probe P1 to NE was evaluated in buffered aqueous solution at 
pH 6.5 (phosphate, 10 mM) because a preliminary screening showed that this pH gave the best 
results. Thus when NE (1000 µM) was added to a red-colored suspension of P1, a clear color 
change, from red to blue was rapidly observed, and indicated the aggregation of the gold 
nanoparticles. A remarkable shift of the SPR band from 523 to 621 nm was observed in the UV-
vis absorption spectrum (Figure 1) due to aggregation-induced interparticle plasmon coupling. 
Aggregation of nanoparticles was also confirmed by TEM (Figure S2 A and B) and DLS. The DLS 
studies showed an increase in the hydrodynamic diameter of the nanoparticles from 20.51 nm for 
P1 to 658.8 nm after the addition of NE (Figure S3 B). Moreover, the Zeta potential lowered from 
-28 mV (P1) to -12 mV (P1+NE) due to the reaction of the recognition moieties with the 
neurotransmitter and to the aggregation of the nanoparticles (Figure S4). The kinetic studies 
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showed a marked increase in the absorbance of P1 at 621 nm after the addition of NE since 
minute 1, reaching its maximum point in around 5 min (Figure S6). 
 
Figure 1. The UV-Vis spectra of P1 in the absence (red) and in the presence (blue) of NE (1000 µM) (pH 6.5 phosphate 
buffer, 10 mM). 
 
The selectivity of P1 toward NE versus other similar neurotransmitters, such as dopamine 
(DA), and epinephrine (Epi), and other biomolecules, e.g., 5-hydroxyindoleacetic acid (5-HIAA, 
the main metabolite of serotonin in urine), L-tyrosine (L-Tyr, precursor of some stimulatory 
neurotransmitters), glucose (Glc), uric acid (UA, a potential neurotransmitter), lysine (Lys) and 
glutamic acid (GA, excitatory amino acid) was also evaluated. Upon the addition of these potential 
interferences to the suspension of P1, negligible changes in the color or in the A621/A523 ratio (A621 
= absorbance at 621 nm, A523 = absorbance at 523 nm) of the solutions were observed (Figures 
2 and S7, S8). Finally, a competitive experiment was performed to evaluate the response of P1 
in a mixture containing NE and DA, Epi, L-Tyr, Gcl, UA, Lys, and GA (1000 µM of each). As shown 
in Figure 2b, a similar response to that found for P1 in the presence of NE alone was observed. 
The stability of P1 and its selectivity to NE remained almost unchanged within the 6.5 - 7.5 pH 
range (Figure S9). We attribute this higher selectivity of the probe towards NE versus other similar 
catecholamines such as Da and Epi, to the presence of the aminoalcohol group in NE, which 
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allows the formation of a highly stable oxazolidine upon reaction with the aromatic aldehyde 
attached to the gold nanoparticles. Imine formation is highly unfavourable in water and this would 
explain the fact that we did not observe aggregation in the presence of dopamine which lacks of 
the hydroxyl group. On the other hand, the lower response of the probe towards epinephrine 
under the tested reaction conditions could be a kinetic effect due to the presence of the methyl 
group attached to the nitrogen atom. In fact, as observed in Figure 2, epinephrine also produces 
some aggregation of the nanoparticles although to a much lesser extent. 
 
Figure 2. Response of probe P1 toward relevant biomolecules (1000 µM) at pH 6.5 (phosphate buffer, 10 mM). a) 
Observed colour changes. b) Representation of A621/A523 for NE, the interferents and a mixture of all. 
 
Additionally, control experiments with citrate-capped AuNPs and with AuNPs modified only 
with L1 (L1-AuNPs) or with L2 (L2-AuNPs) (see Supp. Info for details) were also performed. We 
observed the aggregation of the citrate-AuNPs in the presence of excess of all the catecholamines 
(1000 μM) [50], whereas negligible changes in the color or in the A621/A523 ratio of the solutions 
were observed upon the addition of an excess of NE, EPI or DA to the suspensions of L1-AuNPs 
or L2-AuNPs. Finally, the response observed in the A621/A523 ratio for an equimolecular mixture 
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of L1-AuNPs and L2-AuNPs in the presence of NE (100 μM) was much lower than that observed 
in the presence of P1 (see Supporting Information, Fig S13). 
 
In order to evaluate the sensitivity of probe P1, UV-vis titration experiments were 
performed in the presence of increasing amounts of NE. As observed in Figure 3a, the addition 
of NE to an aqueous suspension of P1 induced a gradual color modulation that went from clear 
red to purple, and finally to blue. The corresponding bathochromic shift of the SPR absorption 
band of P1 with increasing NE concentrations was also observed in the corresponding UV-vis 
spectra (Figure 3b), and can be attributed to the analyte-induced aggregation of nanoparticles. 
From the A621/A523 vs. the NE concentration plot, a limit of detection (LOD) of 1.16 µM was 
determined (Figure 4b curve 2 and Figure S14). 
 
Figure 3. a) Color variation of P1 after the addition of NE at the 0, 50, 100, 200, 300, 400, 500, 600, 700, 800, 900 and 
1000 µM concentrations (1-12, respectively). b) Changes in the UV-Vis spectra of P1 upon addition of NE at 0, 50, 100, 
200, 300, 400, 500, 600, 700, 800, 900 and 1000 µM concentrations at pH 6.5 (phosphate buffer, 10 mM) 
 
As shown in Figure 4a, a slight linear increase in the A621/A523 ratio with increasing NE 
concentrations was observed within the 0–500 µM concentration range. Interestingly, a much 
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more marked intensity increase was observed within the 500-1200 µM concentration range. This 
fact allowed to improve the sensitivity to NE detection by simply adding a certain fixed amount of 
NE to the stock solution of P1 immediately before use. [38] Thus an optimized probe (OP1) was 
prepared by adding 500 µM of NE to the P1 solution in advance. As observed in the A621/A523 vs. 
the NE concentration plot for OP1 (Figure 4b, curve 1), sensitivity is greater than it is for P1. From 
this plot, a LOD of 0.07 µM could be determined (see Figure S15). This low LOD of OP1 is 
indicative of the remarkable sensitivity of the optimized probe, conferring the system the possibility 
of detecting NE at relevant clinical concentrations. 
 
Figure 4. a) Plot of A621/A523 versus NE concentration (0-1500 µM) for P1. b) Linear plots of A621/A523 versus the NE 
concentration obtained with (1) OP1 and (2) P1. 
 
The normal range for norepinephrine in healthy individuals is 0.08 to 0.47 µM in urine. 
Reported studies determined that higher NE levels could be indicative of pheochromocytoma and 
paraganglioma tumors. [51] Given the interest in the determination of NE concentration in urine, 
we decided to test the response of OP1 in this highly competitive media.[52] OP1 in urine showed 
a similar behavior to that described before in aqueous media upon the addition of increasing 
concentrations of NE (Figure S16). The plot of A621/A523 vs. NE concentration in urine shows a 
linear response within the 0 - 1 µM concentration range (Figure 5). The determined LOD in this 






















Figure 5. Linear plot of A621/A523 versus the NE concentration obtained with OP1 in urine samples 
 
4. Conclusions  
In short, we have developed a new approach for the selective and sensitive colorimetric 
detection of NE using bifunctionalized gold nanoparticles based on a double recognition process. 
Probe P1, consisting of AuNPs functionalized with boronic acid and aldehyde-terminated ligands, 
selectively reacted with the catechol group and the aminoalcohol moiety of NE in aqueous 
buffered solution, and led to nanoparticle aggregation. This resulted in a remarkable color change 
in the solution from red to blue, and the appearance of a new absorption band at 621 nm in the 
UV-vis spectrum. Due to this double interaction, P1 showed excellent selectivity to NE, whereas 
almost no response of the probe was observed for similar neurotransmitters (dopamine, and 
epinephrine) or selected biomolecules (5-hydroxyindoleacetic acid, L-tyrosine, glucose, uric acid, 
lysine and glutamic acid). An optimized probe (OP1) was prepared by adding a certain fixed 
amount of NE to the probe before using it. OP1 showed a linear response to NE within the 0-1 
µM range in buffered water at pH 6.5, with a calculated LOD of 0.07 µM. A similar response to 
NE in synthetic urine could be observed, with a LOD in this medium of 0.09 µM. To conclude, our 
system allows the rapid, cheap, selective and sensitive detection of NE by overcoming some of 
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the limitations of current methods. We think that our findings could help to early diagnoses 
diseases such as pheochromocytoma or paraganglioma for which NE is an important biomarker. 
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